Page 17 - Hormel Report 2023

| 17
The optimized AAV purification method developed in Aslanidi lab – from cellular lysate to high-purity vectors.
PUBLICATION HIGHLIGHTS:
• Krotova, K., Kuoch, H., Caine, C., & Aslanidi, G. (2023). Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model. Molecular Therapy - Methods and Clinical Development, 28, 301-311.
• Kuoch, H., Krotova, K., Graham, M. L., Brantly, M. L., & Aslanidi, G. (2023). Multiplexing AAV Serotype- Specific Neutralizing Antibodies in Preclinical Animal Models and Humans. Biomedicines, 11(2), 523.
• Hoffmann, M. D., Zdechlik, A. C., He, Y., Nedrud, D., Aslanidi, G., Gordon, W., & Schmidt, D. (2023). Multiparametric domain insertional profiling of Adeno-Associated Virus VP1. bioRxiv.
• Kwak, G., Gololobova, O., Sharma, N., Caine, C., Mazur, M., Mulka, K., West, N. E., Solomon, G. M., Cutting, G. R., Witwer, K. W., Rowe, S. M., Paulaitis, M., Aslanidi, G., & Suk, J. S. (2023). Extracellular vesicles enhance pulmonary transduction of stably associated adeno-associated virus following intratracheal administration. J Extracell Vesicles, 12(6), e12324.
therapies. We already administrated our vaccine to seven dogs and are following the outcomes of treatment. Our study presented for the first time the safety of AAV cancer vaccine with tumor antigens in dogs with spontaneous cancer. Testing of that vaccine on a clinically relevant animal model will provide the necessary data to determine if advancement into human clinical trials is warranted.
ORCID iD: https://orcid.org/0000-0002-2726-8627
Aslanidi lab presenting data at American Society Gene & Cell Therapy Annual Meeting 2023 The family of ultra-rare Cockayne syndrome patient living in Austin is visiting Aslanidi lab